NEO icon

NeoGenomics

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 76.5%
Negative

Neutral
Business Wire
4 days ago
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced the launch of RaDaR® ST, its circulating tumor DNA assay for detecting molecular residual disease.
NeoGenomics Launches RaDaR ST, Expanding Molecular Residual Disease Testing Across Multiple Solid Tumor Types
Negative
Zacks Investment Research
9 days ago
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
Neutral
Business Wire
11 days ago
NeoGenomics to Participate in Upcoming Investor Conferences
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the TD Cowen 46th Annual Health Care Conference in Boston and the Leerink Global Healthcare Conference in Miami.
NeoGenomics to Participate in Upcoming Investor Conferences
Neutral
Seeking Alpha
12 days ago
NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q4 2025 Earnings Call Transcript
Positive
Zacks Investment Research
12 days ago
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago.
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
Neutral
Business Wire
12 days ago
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its fourth-quarter and full-year results for the period ended December 31, 2025.
NeoGenomics Reports Fourth Quarter and Full Year 2025 Results
Positive
Zacks Investment Research
13 days ago
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
NEO launches PanTracer Pro, a pan-solid tumor assay built to streamline genomic testing and speed treatment decisions in advanced cancers.
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
Neutral
Business Wire
17 days ago
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics launches PanTracer Pro, designed to help clinicians navigate complex molecular testing and support informed solid tumor decisions.
NeoGenomics Introduces PanTracer Pro to Support Timely, Informed Solid Tumor Therapy Selection
Neutral
Business Wire
1 month ago
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its fourth quarter and full year 2025 financial results prior to the open of the U.S. financial markets on Feb. 17, 2026.
NeoGenomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026
Positive
Seeking Alpha
1 month ago
NeoGenomics: Distribution Moat In Community Oncology
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration.
NeoGenomics: Distribution Moat In Community Oncology